Slow low-dose oral immunotherapy: Threshold and immunological change
Background: We examined the feasibility, efficacy and safety of slow low-dose oral immunotherapy (SLOIT) for egg, milk, wheat allergies, with accepted severity-stratified initial and maintenance doses. Methods: Children with food allergies defined by low-dose oral food challenges (LD-OFCs) to hen...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893020300423 |
id |
doaj-bd2d46a01d894b158b38f5d31ead722d |
---|---|
record_format |
Article |
spelling |
doaj-bd2d46a01d894b158b38f5d31ead722d2020-11-25T03:25:59ZengElsevierAllergology International1323-89302020-10-01694601609Slow low-dose oral immunotherapy: Threshold and immunological changeShiro Sugiura0Katsumasa Kitamura1Atsushi Makino2Teruaki Matsui3Tomoko Furuta4Yoshihiro Takasato5Naoyuki Kando6Komei Ito7Corresponding author. Department of Allergy, Aichi Children's Health and Medical Center, 7-426, Morioka, Obu, Aichi 474-8710, Japan.; Department of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Obu, JapanBackground: We examined the feasibility, efficacy and safety of slow low-dose oral immunotherapy (SLOIT) for egg, milk, wheat allergies, with accepted severity-stratified initial and maintenance doses. Methods: Children with food allergies defined by low-dose oral food challenges (LD-OFCs) to hen's egg (cumulative protein dose up to 983 mg, n = 133), cow's milk (287 mg, n = 50), and wheat (226 mg, n = 45) were recruited. Participants were divided into two groups [SLOIT and control (complete avoidance]) based on their preferences. Participants who selected SLOIT were instructed to take the safe dose daily, with monthly increases, aiming to increase the dose by 10 times in one year. The primary outcome was the proportion of participants who passed the LD-OFCs following 1 year of therapy. Results: The participants in SLOIT group ingested their antigen 92.9% of the therapy's day on average. The proportion of participants who passed LD-OFCs was 35.9% (61/170) in the SLOIT group and 8.7% (4/46) in the control group (P < .001); no large differences were observed among allergens. Among the subjects who failed LD-OFCs, the median change in the total dose in the LD-OFC was 235% (interquartile range: 100%–512%) in the SLOIT group and 100% (42%–235%) in the control group (P < .001). Provoked allergic symptoms were observed in only 0.58% (280/48,486) per programmed intake and approximately 50% of the SLOIT group did not experience any obvious allergic symptoms throughout therapy. Conclusions: SLOIT showed significant feasibility, efficacy and safety, providing a promising option to manage patients with severe food allergies.http://www.sciencedirect.com/science/article/pii/S1323893020300423Food allergyInitial doseMaintenance doseOral food challengesOral immunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shiro Sugiura Katsumasa Kitamura Atsushi Makino Teruaki Matsui Tomoko Furuta Yoshihiro Takasato Naoyuki Kando Komei Ito |
spellingShingle |
Shiro Sugiura Katsumasa Kitamura Atsushi Makino Teruaki Matsui Tomoko Furuta Yoshihiro Takasato Naoyuki Kando Komei Ito Slow low-dose oral immunotherapy: Threshold and immunological change Allergology International Food allergy Initial dose Maintenance dose Oral food challenges Oral immunotherapy |
author_facet |
Shiro Sugiura Katsumasa Kitamura Atsushi Makino Teruaki Matsui Tomoko Furuta Yoshihiro Takasato Naoyuki Kando Komei Ito |
author_sort |
Shiro Sugiura |
title |
Slow low-dose oral immunotherapy: Threshold and immunological change |
title_short |
Slow low-dose oral immunotherapy: Threshold and immunological change |
title_full |
Slow low-dose oral immunotherapy: Threshold and immunological change |
title_fullStr |
Slow low-dose oral immunotherapy: Threshold and immunological change |
title_full_unstemmed |
Slow low-dose oral immunotherapy: Threshold and immunological change |
title_sort |
slow low-dose oral immunotherapy: threshold and immunological change |
publisher |
Elsevier |
series |
Allergology International |
issn |
1323-8930 |
publishDate |
2020-10-01 |
description |
Background: We examined the feasibility, efficacy and safety of slow low-dose oral immunotherapy (SLOIT) for egg, milk, wheat allergies, with accepted severity-stratified initial and maintenance doses. Methods: Children with food allergies defined by low-dose oral food challenges (LD-OFCs) to hen's egg (cumulative protein dose up to 983 mg, n = 133), cow's milk (287 mg, n = 50), and wheat (226 mg, n = 45) were recruited. Participants were divided into two groups [SLOIT and control (complete avoidance]) based on their preferences. Participants who selected SLOIT were instructed to take the safe dose daily, with monthly increases, aiming to increase the dose by 10 times in one year. The primary outcome was the proportion of participants who passed the LD-OFCs following 1 year of therapy. Results: The participants in SLOIT group ingested their antigen 92.9% of the therapy's day on average. The proportion of participants who passed LD-OFCs was 35.9% (61/170) in the SLOIT group and 8.7% (4/46) in the control group (P < .001); no large differences were observed among allergens. Among the subjects who failed LD-OFCs, the median change in the total dose in the LD-OFC was 235% (interquartile range: 100%–512%) in the SLOIT group and 100% (42%–235%) in the control group (P < .001). Provoked allergic symptoms were observed in only 0.58% (280/48,486) per programmed intake and approximately 50% of the SLOIT group did not experience any obvious allergic symptoms throughout therapy. Conclusions: SLOIT showed significant feasibility, efficacy and safety, providing a promising option to manage patients with severe food allergies. |
topic |
Food allergy Initial dose Maintenance dose Oral food challenges Oral immunotherapy |
url |
http://www.sciencedirect.com/science/article/pii/S1323893020300423 |
work_keys_str_mv |
AT shirosugiura slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT katsumasakitamura slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT atsushimakino slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT teruakimatsui slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT tomokofuruta slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT yoshihirotakasato slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT naoyukikando slowlowdoseoralimmunotherapythresholdandimmunologicalchange AT komeiito slowlowdoseoralimmunotherapythresholdandimmunologicalchange |
_version_ |
1724594583233363968 |